AR110629A1 - Construcciones de arni para inhibir expresión de asgr1 y métodos para su uso - Google Patents

Construcciones de arni para inhibir expresión de asgr1 y métodos para su uso

Info

Publication number
AR110629A1
AR110629A1 ARP170102382A ARP170102382A AR110629A1 AR 110629 A1 AR110629 A1 AR 110629A1 AR P170102382 A ARP170102382 A AR P170102382A AR P170102382 A ARP170102382 A AR P170102382A AR 110629 A1 AR110629 A1 AR 110629A1
Authority
AR
Argentina
Prior art keywords
rnai
asgr1
rnai construct
methods
expression
Prior art date
Application number
ARP170102382A
Other languages
English (en)
Spanish (es)
Inventor
Yuan Cheng
John Gordon Allen
Bin Wu
Leslie P Miranda
Kaustav Biswas
Yuang Li
Chawita Netirojjanakul
Oh Kyu Yoon
Justin K Murray
Oliver Homann
Jun Zhang
Michael Ollmann
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of AR110629A1 publication Critical patent/AR110629A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/332—Abasic residue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3513—Protein; Peptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
ARP170102382A 2016-08-26 2017-08-28 Construcciones de arni para inhibir expresión de asgr1 y métodos para su uso AR110629A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662380216P 2016-08-26 2016-08-26

Publications (1)

Publication Number Publication Date
AR110629A1 true AR110629A1 (es) 2019-04-17

Family

ID=59846644

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP170102382A AR110629A1 (es) 2016-08-26 2017-08-28 Construcciones de arni para inhibir expresión de asgr1 y métodos para su uso

Country Status (10)

Country Link
US (2) US10870856B2 (enExample)
EP (1) EP3504333A1 (enExample)
JP (4) JP7082610B2 (enExample)
AR (1) AR110629A1 (enExample)
AU (2) AU2017315952B2 (enExample)
CA (2) CA3034463C (enExample)
MX (2) MX2019002271A (enExample)
TW (1) TW201823461A (enExample)
UY (1) UY37376A (enExample)
WO (1) WO2018039647A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016332900C1 (en) * 2015-09-29 2024-07-04 Amgen Inc. ASGR inhibitors
MA68842B1 (fr) 2017-08-04 2025-01-31 Amgen Inc. Procédé de conjugaison de cys-mabs
CN111212909A (zh) * 2017-10-17 2020-05-29 箭头药业股份有限公司 用于抑制去唾液酸糖蛋白受体1的表达的RNAi试剂和组合物
CA3078971A1 (en) * 2017-11-01 2019-05-09 Alnylam Pharmaceuticals, Inc. Complement component c3 irna compositions and methods of use thereof
KR102798620B1 (ko) * 2018-06-07 2025-04-22 암젠 인크 단백질-폴리뉴클레오티드 접합체에 대한 검출 검정
SG11202105900UA (en) * 2018-12-10 2021-07-29 Amgen Inc CHEMICALLY-MODIFIED RNAi CONSTRUCTS AND USES THEREOF
SG11202113112WA (en) * 2019-05-30 2021-12-30 Amgen Inc Rnai constructs for inhibiting scap expression and methods of use thereof
CA3143047A1 (en) 2019-06-25 2020-12-30 Amgen Inc. Purification methods for carbohydrate-linked oligonucleotides
EP4126967A1 (en) 2020-03-23 2023-02-08 Amgen Inc. Monoclonal antibodies to chemically-modified nucleic acids and uses thereof
CN111705063B (zh) * 2020-06-02 2023-08-08 成都中科奥格生物科技有限公司 Asgr1突变基因及其在制备哺乳动物肝损伤敏感模型中的应用
KR20240082367A (ko) * 2021-09-23 2024-06-10 아르네이 사이언시스 엘엘씨 치료학적 물질로서 고리형 구조의 올리고뉴클레오티드
WO2024046297A1 (zh) * 2022-09-02 2024-03-07 北京福元医药股份有限公司 抑制去唾液酸糖蛋白受体基因表达的siRNA、其缀合物和药物组合物及用途
WO2025231448A2 (en) * 2024-05-03 2025-11-06 University Of Massachusetts Oligonucleotides targeting myostatin (mstn)

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5714331A (en) 1991-05-24 1998-02-03 Buchardt, Deceased; Ole Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
US5719262A (en) 1993-11-22 1998-02-17 Buchardt, Deceased; Ole Peptide nucleic acids having amino acid side chains
US5539082A (en) 1993-04-26 1996-07-23 Nielsen; Peter E. Peptide nucleic acids
US5981505A (en) 1993-01-26 1999-11-09 The Trustees Of The University Of Pennsylvania Compositions and methods for delivery of genetic material
US5837533A (en) 1994-09-28 1998-11-17 American Home Products Corporation Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent
US5840710A (en) 1994-12-09 1998-11-24 Genzyme Corporation Cationic amphiphiles containing ester or ether-linked lipophilic groups for intracellular delivery of therapeutic molecules
US5981501A (en) 1995-06-07 1999-11-09 Inex Pharmaceuticals Corp. Methods for encapsulating plasmids in lipid bilayers
US7422902B1 (en) 1995-06-07 2008-09-09 The University Of British Columbia Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
JP4335310B2 (ja) 1995-06-07 2009-09-30 ザ ユニバーシティ オブ ブリティッシュ コロンビア 疎水性脂質−核酸複合中間体を通して調製される脂質−核酸粒子、及び遺伝子移送のための使用
US6217900B1 (en) 1997-04-30 2001-04-17 American Home Products Corporation Vesicular complexes and methods of making and using the same
WO1999001579A1 (en) 1997-07-01 1999-01-14 Isis Pharmaceuticals, Inc. Compositions and methods for the delivery of oligonucleotides via the alimentary canal
ATE237312T1 (de) 1998-07-20 2003-05-15 Protiva Biotherapeutics Inc In liposomen verkapselte nukleinsäurekomplexe
US7491805B2 (en) 2001-05-18 2009-02-17 Sirna Therapeutics, Inc. Conjugates and compositions for cellular delivery
US7833992B2 (en) 2001-05-18 2010-11-16 Merck Sharpe & Dohme Conjugates and compositions for cellular delivery
US6693187B1 (en) 2000-10-17 2004-02-17 Lievre Cornu Llc Phosphinoamidite carboxlates and analogs thereof in the synthesis of oligonucleotides having reduced internucleotide charge
US7109165B2 (en) 2001-05-18 2006-09-19 Sirna Therapeutics, Inc. Conjugates and compositions for cellular delivery
US20030130186A1 (en) 2001-07-20 2003-07-10 Chandra Vargeese Conjugates and compositions for cellular delivery
US9181551B2 (en) 2002-02-20 2015-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
CA2487274A1 (en) 2002-05-06 2003-11-13 Nucleonics Inc. Spermine chemically linked to lipids and cell-specific targeting molecules as a transfection agent
EP2305813A3 (en) * 2002-11-14 2012-03-28 Dharmacon, Inc. Fuctional and hyperfunctional sirna
EP2669377A3 (en) 2003-04-17 2015-10-14 Alnylam Pharmaceuticals Inc. Modified iRNA agents
US8017762B2 (en) 2003-04-17 2011-09-13 Alnylam Pharmaceuticals, Inc. Modified iRNA agents
US7851615B2 (en) 2003-04-17 2010-12-14 Alnylam Pharmaceuticals, Inc. Lipophilic conjugated iRNA agents
US7723509B2 (en) 2003-04-17 2010-05-25 Alnylam Pharmaceuticals IRNA agents with biocleavable tethers
EP2465534B1 (en) * 2004-06-10 2017-03-29 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
CN1300312C (zh) 2004-08-23 2007-02-14 中国人民解放军军事医学科学院放射与辐射医学研究所 靶向去唾液酸糖蛋白受体的抗乙型肝炎病毒反义寡核苷酸的结构和用途
TR201808537T4 (tr) 2004-09-23 2018-07-23 Genentech Inc Sistein değiştirilmiş antikorlar ve konjugatlar.
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
JP2007285749A (ja) * 2006-04-13 2007-11-01 Kitasato Gakuen インフルエンザ感染検査薬及び検査方法
CN101500548A (zh) * 2006-08-18 2009-08-05 弗·哈夫曼-拉罗切有限公司 用于体内递送多核苷酸的多缀合物
JP4889437B2 (ja) * 2006-10-16 2012-03-07 オリンパス株式会社 微弱光撮像装置
JP2008241447A (ja) * 2007-03-27 2008-10-09 Fujifilm Corp 画像読取装置及び画像読取方法
WO2008131419A2 (en) 2007-04-23 2008-10-30 Alnylam Pharmaceuticals, Inc. Glycoconjugates of rna interference agents
JP5265140B2 (ja) * 2007-06-14 2013-08-14 学校法人日本医科大学 卵巣癌の検出方法及び検出用キット
EP2229186A2 (en) 2007-12-04 2010-09-22 Alnylam Pharmaceuticals Inc. Carbohydrate conjugates as delivery agents for oligonucleotides
JP2010271078A (ja) * 2009-05-19 2010-12-02 Mcbi:Kk 認知機能障害疾患を含む精神疾患のバイオマーカーおよび該バイオマーカーを用いた認知機能障害疾患を含む精神疾患の検出方法
EP2507419A4 (en) 2009-12-01 2013-07-17 Univ Indiana Res & Tech Corp METHOD FOR MODULATING THROMBOCYTOPENIA AND MODIFIED TRANSGENIC PIGS
DK2694108T3 (en) * 2011-04-08 2018-08-20 Univ Leicester METHODS OF TREATING DISEASES ASSOCIATED WITH MASP-2 DEPENDENT COMPLEMENT ACTIVATION
WO2012177639A2 (en) * 2011-06-22 2012-12-27 Alnylam Pharmaceuticals, Inc. Bioprocessing and bioproduction using avian cell lines
AR090905A1 (es) 2012-05-02 2014-12-17 Merck Sharp & Dohme Conjugados que contienen tetragalnac y peptidos y procedimientos para la administracion de oligonucleotidos, composicion farmaceutica
WO2014205451A2 (en) 2013-06-21 2014-12-24 Isis Pharmaceuticals, Inc. Compositions and methods for modulation of target nucleic acids
EP3286318A2 (en) * 2015-04-22 2018-02-28 Mina Therapeutics Limited Sarna compositions and methods of use
AU2016332900C1 (en) * 2015-09-29 2024-07-04 Amgen Inc. ASGR inhibitors

Also Published As

Publication number Publication date
JP7082610B2 (ja) 2022-06-08
JP2022060357A (ja) 2022-04-14
JP7472180B2 (ja) 2024-04-22
US11732266B2 (en) 2023-08-22
WO2018039647A1 (en) 2018-03-01
AU2024201349B2 (en) 2026-07-30
CA3277899A1 (en) 2026-03-02
US20210108212A1 (en) 2021-04-15
CA3034463A1 (en) 2018-03-01
JP2024019733A (ja) 2024-02-09
TW201823461A (zh) 2018-07-01
US20190309306A1 (en) 2019-10-10
AU2024201349A1 (en) 2024-04-11
JP2019524151A (ja) 2019-09-05
EP3504333A1 (en) 2019-07-03
AU2017315952A1 (en) 2019-03-14
CA3034463C (en) 2025-09-16
MX2024009873A (es) 2024-08-20
AU2017315952B2 (en) 2023-11-30
JP2026083134A (ja) 2026-05-19
JP7873261B2 (ja) 2026-06-11
US10870856B2 (en) 2020-12-22
UY37376A (es) 2018-03-23
MX2019002271A (es) 2019-06-20

Similar Documents

Publication Publication Date Title
UY37376A (es) Construcciones de arni para inhibir expresión de asgr1 y métodos para su uso
CL2020001543A1 (es) Constructos de arni para inhibir la expresión de pnpla3 y métodos de uso de los mismos.
Ding et al. LOX-1, oxidant stress, mtDNA damage, autophagy, and immune response in atherosclerosis
Moon et al. Diet-induced hypercholesterolemia promotes androgen-independent prostate cancer metastasis via IQGAP1 and caveolin-1
JOP20230030A1 (ar) بنيات RNAi وطرق لتثبيط التعبير عن MARC1
CR20210371A (es) Constructos de arni para inhibir la expresión de pnpla3
Tang et al. MiR-20b-5p modulates inflammation, apoptosis and angiogenesis in severe acute pancreatitis through autophagy by targeting AKT3
CL2013003214A1 (es) Formulacion estable que comprende al menos un anticuerpo monoclonal que se une especificamente a pcsk9, un tampon, un surfactante y al menos un estabilizador; y su uso para tratar o prevenir enfermedades relacionadas con el colesterol.
MX2024007140A (es) Conjugados de farmaco-proteina con ciclodextrina.
EA201990438A1 (ru) Композиции, содержащие 5-холестен-3,25-диол, 3-сульфат (25hc3s) или его фармацевтически приемлемую соль и по меньшей мере один циклический олигосахарид, и способы их применения
MY162715A (en) Modulation of apolipoprotein ciii (apociii) expression
Huang et al. Expression of micro RNA‐122 contributes to apoptosis in H9C2 myocytes
UY37630A (es) Combinación farmacéutica, kit, célula huésped que la produce y su uso en métodos para el tratamiento del cáncer
Jiang et al. MiR-144-3p induced by SP1 promotes IL-1β-induced pyroptosis in chondrocytes via PTEN/PINK1/Parkin axis
CL2021003169A1 (es) Construcciones de arni para inhibir la expresión de scap y métodos de uso de las mismas
CL2024001326A1 (es) Terapia combinada de inhibidores de cd73 e inhibidores de los receptores de adenosina a2a/a2b.
Ling et al. 2, 3, 5, 4′‐Tetrahydroxystilbene‐2‐O‐β‐D‐glucoside promotes expression of the longevity gene klotho
Waaijer et al. MicroRNA-663 induction upon oxidative stress in cultured human fibroblasts depends on the chronological age of the donor
CL2024002802A1 (es) Constructos de arni para inhibir la expresión de pnpla3 y métodos de uso de los mismos
CL2024001214A1 (es) Constructos de arni para inhibir la expresión de gpam y métodos de uso.
CL2024003564A1 (es) Constructos de arni para inhibir la expresión de scap y métodos de utilización de los mismos
Moon et al. Steroid Failure At Day 28 After Acute Graft-Versus-Host Disease Treatment and Long-Term Outcomes Following Allogeneic Transplantation: Adverse Impact On Survival and Non-Relapse Mortality But No Increasing Risk Of Relapse
Oita et al. D43 CELL FATE: The Role Of Nampt/pbef In Regulating Pro-Survival Mechanisms In Endothelial Cells Through An Nmn-Independent Mechanism
Kemlink et al. Restless legs syndrome during pregnancy in Czech women
Li et al. OR22: LIGATION OF HLA CLASS II MOLECULES BY HLA ANTIBODIES INDUCES ENDOTHELIAL CELL PERMEABILITY AND MONOCYTE TRANSENDOTHELIAL MIGRATION

Legal Events

Date Code Title Description
FB Suspension of granting procedure